Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Monday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Trading Up 7.2 %

NASDAQ CHEK opened at $1.34 on Monday. The company has a market cap of $7.84 million, a price-to-earnings ratio of -0.45 and a beta of 0.39. Check-Cap has a 1-year low of $1.13 and a 1-year high of $3.99. The company has a 50 day moving average of $1.82 and a 200-day moving average of $2.08.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.